Price Alert

ARS Pharmaceuticals Inc. (SPRY)

NASDAQ: SPRY · Real-Time Price · USD

14.63

0.16 (1.11%)

At close: Aug 15, 2025, 1:14 PM

1.11% (1D)

Bid	10.65
Market Cap	1.44B
Revenue (ttm)	97.12M
Net Income (ttm)	-15.65M
EPS (ttm)	-0.48
PE Ratio (ttm)	-30.48
Forward PE	-27.36
Analyst	Buy

Ask	14.67
Volume	1,096,401
Avg. Volume (20D)	1,468,120
Open	14.40
Previous Close	14.47
Day's Range	14.26 - 14.91
52-Week Range	10.00 - 18.90
Beta	0.89

About SPRY

undefined

[Read more]

Industry n/a

Sector n/a

IPO Date n/a

Employees NaN

Stock Exchange n/a

Ticker Symbol SPRY

Website n/a

Full Company Profile

Analyst Forecast

According to 0 analyst ratings, the average rating for SPRY stock is "n/a." The 12-month stock price forecast is $n/a, which is a decrease of 0% from the latest price.

Stock Forecasts

Earnings Surprise

ARS Pharmaceuticals has released their quartely earnings on Aug 13, 2025:

Revenue of $15.72M exceeds estimates by $1.4M, with 3043.40% YoY growth.

EPS of -0.46 exceeds estimates by 0.01, with -253.85% YoY decline.

Next Earnings Release

ARS Pharmaceuticals Inc. is scheduled to release its earnings on Nov 12, 2025, before market opens.
Analysts project revenue of ... Unlock content with Pro Subscription

Why Price Moved

2 days ago

-5.04%

ARS Pharmaceuticals shares are trading lower follo... Unlock content with Pro Subscription

3 months ago

+11.48%

ARS Pharmaceuticals shares are trading higher on possible continued strength after reporting a Q1 revenue beat earlier mid-week.

News

1 day ago · seekingalpha.com

ARS Pharmaceuticals, Inc. (SPRY) Q2 2025 Earnings Call Transcript

ARS Pharmaceuticals, Inc. (NASDAQ:SPRY ) Q2 2025 Earnings Conference Call August 13, 2025 8:30 AM ET Company Participants Eric Karas - Chief Commercial Officer Justin Chakma - Chief Business Officer K...

1 day ago · zacks.com

ARS Pharmaceuticals, Inc. (SPRY) Reports Q2 Loss, Beats Revenue Estimates

ARS Pharmaceuticals, Inc. (SPRY) came out with a quarterly loss of $0.46 per share versus the Zacks Consensus Estimate of a loss of $0.41. This compares to a loss of $0.13 per share a year ago.

2 weeks ago · zacks.com

Analysts Estimate ARS Pharmaceuticals, Inc. (SPRY) to Report a Decline in Earnings: What to Look Out for

ARS Pharmaceuticals, Inc. (SPRY) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

1 month ago · zacks.com

ARS Pharmaceuticals, Inc. (SPRY) is a Great Momentum Stock: Should You Buy?

Does ARS Pharmaceuticals, Inc. (SPRY) have what it takes to be a top stock pick for momentum investors? Let's find out.

1 month ago · zacks.com

Wall Street Analysts See a 78.77% Upside in ARS Pharmaceuticals, Inc. (SPRY): Can the Stock Really Move This High?

The mean of analysts' price targets for ARS Pharmaceuticals, Inc. (SPRY) points to a 78.8% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreem...

1 month ago · zacks.com

What Makes ARS Pharmaceuticals, Inc. (SPRY) a Good Fit for 'Trend Investing'

ARS Pharmaceuticals, Inc. (SPRY) could be a great choice for investors looking to make a profit from fundamentally strong stocks that are currently on the move. It is one of the several stocks that ma...